Xaparin 4000 Anti-Xa IU/0.4 ml (SC Injection)

Indications

• Treatment of deep vein thrombosis with or without pulmonary embolism
• Treatment of unstable angina and non-Q-wave myocardial infarction
• Prevention of thrombus formation in the extra-corporeal circulation during haemodialysis
• Prophylaxis of venous thromboembolic disease in surgical and medical patients

Dosage

• Subcutaneously 100 anti-Xa lU/kg twice daily for 10 days
• Subcutaneously 150 anti-Xa lU/kg once daily for 10 days
• Subcutaneously 100 anti-Xa lU/kg twice daily for 2- 8 days
• Recommended dose of 100 anti-Xa lU/kg during hemodialysis
• Subcutaneously 2000 anti-Xa IU (0.2 ml) or 4000 anti-Xa IU (0.4 ml) once daily for 7 to 10 days for general surgery patients
• Subcutaneously 4000 anti-Xa IU (0.4 ml) once daily for 7 to 10 days for orthopedic surgery patients
• Subcutaneously 4000 anti-Xa IU (0.4 ml) once daily for 6- 14 days for medical patients

Composition

• Each 0.2 ml pre-filled syringe contains Enoxaparin Sodium BP 20 mg
• Each 0.4 ml pre-filled syringe contains Enoxaparin Sodium BP 40 mg
• Each 0.6 ml pre-filled syringe contains Enoxaparin Sodium BP 60 mg
• Each 0.8 ml pre-filled syringe contains Enoxaparin Sodium BP 80 mg

Pharmacology

Low molecular weight heparin with high anti-Xa activity and low anti-lla activity. Metabolized in the liver.

Administration

• Instructions on injecting yourself with Enoxaparin Sodium Syringes
• Preparing the injection site
• Selecting your dose
• Injecting
• After injection

Interaction

Recommendation to discontinue agents affecting hemostasis prior to Xaparin therapy

Contraindications

Hypersensitivity to Enoxaparin Sodium, heparin, or other low molecular weight heparins. Active major bleeding. High risk of uncontrolled hemorrhage.

Side Effects

• Haemorrhage (bleeding)
• Thrombocytopenia
• Elevations of serum aminotransferase
• Pain, bluish marks, or skin rash at injection sites
• Cases of neuraxial hematomas with concurrent use of Xaparin and spinal/epidural anesthesia or spinal puncture

Pregnancy & Lactation

Category B. No evidence of crossing placental barrier. Use during pregnancy only if clearly needed. No evidence of excretion in human milk.

Precautions & Warnings

• Deep subcutaneous route for prophylactic and curative treatment
• Caution in conditions with increased potential for bleeding
• Recommended platelet counts measurement before and regularly during treatment

Use in Special Populations

• Dose in Elderly Patients: No dosage adjustment necessary unless kidney function is impaired
• Dose in Renal Impairment: Monitoring for signs and symptoms of bleeding recommended
• Dose in Hepatic Impairment: Caution in hepatically impaired patients

Overdose Effects

Accidental overdosage may lead to hemorrhagic complications

Therapeutic Class

Parenteral anti-coagulants

Storage Conditions

Cool and dry place, protect from light and moisture, do not store above 25°C, keep out of the reach of children

Related Brands

• Xaparin 6000 Anti-Xa IU/0.6 ml (SC Injection) - acme-laboratories-ltd